Company Filing History:
Years Active: 2008-2010
Title: Innovations of Raphael E Pollock in Cancer Research
Introduction
Raphael E Pollock is a prominent inventor based in Houston, TX (US), known for his significant contributions to cancer research. He has been instrumental in developing methods that address hyperproliferative diseases, particularly cancer. With a total of 2 patents, his work focuses on understanding and treating various cancer types.
Latest Patents
Pollock's latest patents include groundbreaking research on "14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types." This patent outlines methods for determining prognosis in subjects with hyperproliferative diseases by assessing the expression and function of 14-3-3 zeta. Additionally, it describes the creation of pharmaceutical agents that modulate apoptosis, detailing the steps of obtaining and testing candidate substances. The patent emphasizes the importance of selecting substances that can effectively modulate the expression and function of 14-3-3 zeta, ultimately leading to the development of pharmaceutical compositions for treating conditions such as breast cancer.
Career Highlights
Pollock is affiliated with the University of Texas System, where he continues to advance his research in cancer treatment. His work has garnered attention for its potential to improve prognosis and therapeutic strategies for patients suffering from various forms of cancer.
Collaborations
Some of Pollock's notable collaborators include Dihua Yu and Jun Yao, who have contributed to his research endeavors in the field of cancer.
Conclusion
Raphael E Pollock's innovative work in cancer research highlights the critical role of understanding molecular targets in developing effective treatments. His patents reflect a commitment to improving patient outcomes through scientific discovery and collaboration.